Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NYX-2925 in Diabetic Peripheral Neuropathic Pain
NCT04146896Phase 2Completed
- Sponsor
- Aptinyx Inc.
- Start
- Nov 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetic polyneuropathy (DPN) comparing NYX-2925 with Placebo (2 arms). Primary endpoint: Pain Intensity Numeric Rating Scale Score at Week 12. Started Nov 2019; status: completed.
02
Drugs
NYX-2925
03
Conditions
diabetic polyneuropathy (DPN)
Beyond the preview
Go deeper on NCT04146896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04146896.